This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

The Use of Drugs to Improve Kidney Function in Patients With Liver and Kidney Dysfunction

This study has been completed.
Information provided by:
University of Alberta Identifier:
First received: October 13, 2005
Last updated: December 3, 2007
Last verified: October 2005

We will address the hypothesis that refractory ascites and Type 2 hepatorenal syndrome are mediated in part by diminished circulatory volume and that treatment with midodrine, octreotide and albumin can improve renal and patient outcomes by restoring effective circulating volume and systemic perfusion.

Our primary objective is to assess change in creatinine clearance using inulin. We will enroll 15 patients with Type 2 hepatorenal syndrome or refractory ascites once inclusion and exclusion criteria are satisfied. They will be treated for 1 month with octreotide LAR, albumin and midodrine. Renal, serum and neurohormonal parameters will be measured before, during, and after initiation of drug and compared.

Condition Intervention Phase
Type 2 Hepatorenal Syndrome Refractory Ascites Drug: Midodrine, albumin, octreotide LAR Drug: midodrine, octreotide, albumin Phase 2 Phase 3

Study Type: Interventional
Study Design: Allocation: Non-Randomized
Intervention Model: Single Group Assignment
Masking: None (Open Label)
Primary Purpose: Treatment
Official Title: The Use of Midodrine, Octreotide and Albumin in Refractory Ascites

Resource links provided by NLM:

Further study details as provided by University of Alberta:

Primary Outcome Measures:
  • Improvement in renal function (creatinine) [ Time Frame: one month ]

Secondary Outcome Measures:
  • Ascites control [ Time Frame: one month ]

Enrollment: 9
Study Start Date: October 2005
Study Completion Date: July 2007
Arms Assigned Interventions
Experimental: 1 Drug: Midodrine, albumin, octreotide LAR Drug: midodrine, octreotide, albumin
midodrine up to 12.5 mg tid, octreotide LAR 20 mg im once, albumin 150 mg q weekly


Ages Eligible for Study:   19 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Cirrhosis (biopsy or compatible clinical (ascites, varices), laboratory (low albumin, elevated bilirubin, elevated INR) and radiologic data (nodular appearing liver on ultrasound)).

Type 2 hepatorenal syndrome and/or refractory ascites

Exclusion Criteria:

  • Secondary causes of renal dysfunction (proteinuria >500 mg/day, active urinary sediment, abnormal renal ultrasound, nephrotoxic medications) Bacterial infection (positive blood, urine or ascites cultures) within the past 2 weeks Gastrointestinal hemorrhage or encephalopathy within the past 2 weeks Age <18 Transvenous intrahepatic portosystemic stent shunt (TIPS) Hepatocellular carcinoma beyond the Milan criteria
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00240045

Canada, Alberta
University of Alberta
Edmonton, Alberta, Canada, T6G 2E1
Sponsors and Collaborators
University of Alberta
Principal Investigator: Vincent Bain, MD, FRCPC University of Alberta
  More Information

Responsible Party: Dr. Vince Bain, University of Alberta Identifier: NCT00240045     History of Changes
Other Study ID Numbers: VB-PG-007
Study First Received: October 13, 2005
Last Updated: December 3, 2007

Keywords provided by University of Alberta:
Hepatorenal syndrome
Refractory ascites

Additional relevant MeSH terms:
Hepatorenal Syndrome
Pathologic Processes
Liver Diseases
Digestive System Diseases
Kidney Diseases
Urologic Diseases
Gastrointestinal Agents
Antineoplastic Agents, Hormonal
Antineoplastic Agents
Autonomic Agents
Peripheral Nervous System Agents
Physiological Effects of Drugs
Vasoconstrictor Agents
Adrenergic alpha-1 Receptor Agonists
Adrenergic alpha-Agonists
Adrenergic Agonists
Adrenergic Agents
Neurotransmitter Agents
Molecular Mechanisms of Pharmacological Action processed this record on August 18, 2017